Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress. (3rd March 2020)
- Record Type:
- Journal Article
- Title:
- Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress. (3rd March 2020)
- Main Title:
- Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress
- Authors:
- Nabi, Bushra
Rehman, Saleha
Fazil, Mohammad
Khan, Saba
Baboota, Sanjula
Ali, Javed - Abstract:
- Abstract: Purpose: The objective of the research undertaken was to develop the Riluzole (RIZ) nanoparticles drug delivery system using Transferrin (Tf) as a ligand in the brain. Method: RIZ-loaded chitosan nanoparticles and RIZ-Tf chitosan (CS) nanoparticles (RIZ CSNPs and RIZ-Tf CSNPs) were formulated and compared for particles size, size distribution, encapsulation efficiency, and surface morphology, respectively. The in vitro drug release, permeation, pharmacokinetic, biochemical, and pharmacodynamic experiments were done to assess the improvement in in vivo fate and efficacy of RIZ. Results: The size of optimized RIZ CSNPs was found to be 173.6 ± 2.23 nm and polydispersity index (PDI) of 0.264 ± 0.002 while that of RIZ-Tf CSNPs was 207 ± 2.49 nm and 0.406 ± 0.002. In vitro release was found to be 86.15 ± 7.316% and 91.1 ± 5.836%, respectively, while permeability coefficient was found to be 4 × 10 −2 and 4.2 × 10 −2 cm/s for RIZ CSNPs and RIZ-Tf CSNPs. The biochemical analysis studies revealed that oxidative stress was significantly decreased in case of RIZ CSNPs and RIZ-Tf CSNPs ( p < 0.01) treated groups. The antianxiety effect and the memory restoration were evident in pharmacodynamic studies ( p < 0.05) of the prepared formulations. Conclusion: The results of pharmacokinetic studies demonstrated the remarkable brain delivery of RIZ-Tf CSNPs through intranasal route as compared to the RIZ solution.
- Is Part Of:
- Drug development and industrial pharmacy. Volume 46:Number 3(2020)
- Journal:
- Drug development and industrial pharmacy
- Issue:
- Volume 46:Number 3(2020)
- Issue Display:
- Volume 46, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 46
- Issue:
- 3
- Issue Sort Value:
- 2020-0046-0003-0000
- Page Start:
- 471
- Page End:
- 483
- Publication Date:
- 2020-03-03
- Subjects:
- Chitosan -- nanoparticles -- intranasal -- biodistribution -- brain targeting -- riluzole
Pharmaceutical chemistry -- Periodicals
Pharmaceutical industry -- Periodicals
Drug Industry -- Periodicals
Technology, Pharmaceutical -- Periodicals
615.05 - Journal URLs:
- http://informahealthcare.com/loi/ddi ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/03639045.2020.1730396 ↗
- Languages:
- English
- ISSNs:
- 0363-9045
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.116000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13653.xml